Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 20220518090001
Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.
Professor Bertrand Tombal
Professor of Urology
Cliniques universitaires Saint-Luc & Université catholique de Louvain
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Diabetes burden and associated complications
are on the rise in Singapore and contribute to the increasing healthcare expenditure.
Insulin biosimilars, with comparable efficacy and safety to the originator
biologics, can help reduce both financial and disease burden. INSTRIDE-1/2
studies have proven biosimilar insulin glargine to be non-inferior to
reference insulin glargine with no clinically meaningful differences in terms
of efficacy and safety in type 1 and type 2 diabetes patients. Whilst
INSTRIDE-3 has proven the switch from reference glargine to a cost-effective biosimilar
insulin glargine to be a safe and feasible approach. There is a
continued need to educate clinicians to help motivate patients and improve
their awareness on
Various studies have
shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring
system for the continuous monitoring of glucose levels in type 1 and type 2
diabetes (T1D and T2D) patients. While clinical trials have demonstrated a
reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and
significant reduction in glycated haemoglobin (HbA1c), real-world data have
shown improved glycaemic control in these patients.
The FreeStyle Libre™ flash glucose
monitoring system includes a sensor which automatically measures and
continuously stores up to 8 hours of glucose readings, allowing patients to
monitor their glucose levels without the need for painful finger pricks.
Physicians play an important role in reviewing and analysing glucose data
that is available through LibreView to support patient management.
Technological advancements have improved glucose
monitoring and diabetes care, as well as empowered patients in self-care. The
introduction of continuous glucose monitoring systems (CGM), such as the
Abbott FreeStyle LibreTM, offers patients an alternative and
additional advantages to self-monitoring of blood glucose (SMBG).